Release Date: August 12, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- INO-3107 is on track for the October 30, 2026 PDUFA date, with the FDA completing its late-cycle review and all pre-licensure inspections.
- INO-3107 demonstrated strong efficacy in clinical trials, with the majority of patients experiencing a 50-100% reduction in surgery in year one and continued improvement in year two.
- INO-3107 offers a differentiated safety profile, not requiring scoping and surgery during the dosing window, unlike existing treatments like papsimios.
- The company expects to receive seven years of orphan drug market exclusivity for INO-3107 if approved, providing a competitive advantage.
- Positive Phase 3 data from Apollo Bio for VGX-3100 in China validates the potential of Inovio's DNA medicine platform for HPV-related diseases.
- The company has strengthened its balance sheet with an $18.3 million equity offering, extending its cash runway into late first quarter 2027 and through a potential launch.
- Operating expenses decreased by 19% in Q2 2026 compared to the same period in 2025, reflecting disciplined cost management.
Negative Points
- The FDA has not yet provided preliminary conclusions on INO-3107's eligibility for accelerated approval, which remains a potential review issue.
- The company's cash runway extends only into late first quarter 2027, and further capital raising may be needed if launch is delayed or revenue is slower than expected.
- INO-3107 faces competition from papsimios, which has already been approved and has shown early uptake with approximately 200 patients treated.
- The company is still awaiting FDA feedback on the design of the confirmatory trial, which could impact timelines and resources.
- The net loss for Q2 2026 was $6 million, and the company continues to burn cash, with an estimated operational net cash burn of $18 million for Q3 2026.
- The company's reliance on partnerships, such as Apollo Bio for VGX-3100, means it has limited control over the development and commercialization of certain pipeline candidates.
Q & A Highlights
Q: Could you provide more detail on the INO-3107 informal clinical meeting with the FDA and whether any new efficacy, safety, or CMC-related questions were raised?
A: Dr. Mike Sumner, Chief Medical Officer, stated that the FDA granted the meeting, allowing Inovio to present the entirety of the compelling efficacy and safety data for INO-3107. The FDA had already seen the data submitted during the review process, and they did not disagree with Inovio's positioning of the data. However, they were not in a position to comment on the accelerated approval eligibility question as the file is under active review.
Q: Can you provide updates on the confirmatory trial design, including patient population, endpoints, and potential initiation following approval?
A: Dr. Sumner noted that Inovio is still awaiting the FDA's comments on the submitted protocol to the IND. The FDA indicated during the informal meeting that comments would be forthcoming. While this is late in the review process, Inovio has no reason to believe that getting the trial up and running will impact approvability or the PDUFA date.
Q: Should investors expect another capital raise before the PDUFA, or is the plan to bridge launch through revenue and financing partners?
A: CEO Dr. Jackie Shea confirmed that the company is currently funded through late first quarter 2027, which is after the anticipated launch date. CFO Peter Kies added no further comment, affirming that the current funding is sufficient through the projected launch.
Q: Does the first quarter 2027 runway projection bake in prelaunch inventory build and launch marketing spend, or does it assume a straight-to-launch scenario without those costs?
A: CFO Peter Kies clarified that those costs are built into the projections throughout the fourth quarter and first quarter, confirming that the runway estimate includes the necessary prelaunch and launch expenses.
Q: What are the key competitive advantages of INO-3107 compared to existing treatments like Papsimios?
A: Chief Commercial Officer Steve Egge highlighted several advantages: INO-3107 does not require additional scoping and surgeries during the dosing window (unlike Papsimios, where 83% of patients required at least one MRD surgery), minimizing recovery days. It is not impacted by pre-existing neutralizing antibodies or an immunosuppressive papilloma microenvironment, and it does not require specialized ultra-cold chain handling, offering more flexibility in care settings.
Q: What is the status of the FDA's pre-licensure inspections for INO-3107?
A: Dr. Sumner reported that the FDA has completed all scheduled pre-licensure inspections, including clinical, drug manufacturing, in-house drug testing, and the delivery device facility. There was only one reported observation, which Inovio believes it has appropriately addressed and is in the process of submitting its response to the FDA.
Q: What is the expected timeline for label negotiations and the PDUFA date for INO-3107?
A: Dr. Sumner stated that Inovio anticipates starting label negotiations in September, and the company remains on track for the October 30, 2026 target PDUFA date. If approved, Inovio expects to receive seven years of orphan drug market exclusivity for INO-3107.
Q: What were the key financial results for the second quarter of 2026?
A: CFO Peter Kies reported that operating expenses dropped 19% year-over-year to $18.6 million in Q2 2026. The net loss was $6 million, or $0.07 per share, compared to a net loss of $23.5 million, or $0.61 per share, in Q2 2025. The decrease was primarily driven by a $13.9 million non-cash gain on fair value adjustment related to warrant liabilities. The company ended Q2 with $36.7 million in cash and short-term investments.
Q: What is the company's cash runway and operational net cash burn estimate?
A: CFO Peter Kies stated that with the addition of the July public offering (net proceeds of approximately $18.3 million), Inovio expects to extend its cash runway into late first quarter 2027 and through a potential launch of INO-3107. The projection includes an operational net cash burn estimate of approximately $18 million for the third quarter of 2026.
Q: What progress has been made with the VGX-3100 partnership for Greater China?
A: CEO Dr. Jackie Shea highlighted that partner Apollo Bio announced positive top-line results from its pivotal Phase 3 trial of VGX-3100 for cervical dysplasia. The trial met its primary efficacy endpoint of CIN2/CIN3 lesion regression and HPV16/18 viral clearance with a favorable safety profile. Apollo Bio plans to use these results to support a regulatory filing in China, further validating Inovio's DNA medicine platform for HPV-related diseases.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
